HK Stock Market Move | REMEGEN (09995) rose more than 6% during trading. Last year's performance showed a trend of decreasing losses, and the company is expected to submit multiple listing applications this year.

REMEGEN (09995) rose over 6% during trading hours, as of the time of publication, it rose by 5.86%, to HKD 13.36, with a turnover of HKD 225.542 million. In terms of news, REMEGEN recently disclosed its 2024 annual performance forecast. The company expects its 2024 annual revenue to be approximately RMB 1.715 billion, an increase of about 58% year-on-year; it is expected that the net loss attributable to shareholders in the current period will be approximately RMB 1.47 billion, a decrease of about 3% year-on-year. The announcement stated that the company's new drug R&D pipeline continues to advance, with several innovative drugs in key trial research stages, increased R&D investment, as well as rapid growth in sales revenue of Teysirumab and Vidisitumab monoclonal antibodies, continuous increase in product gross margin, and significant decrease in sales expense ratio. Therefore, it is expected that the company will continue to make a net loss in 2024, showing a decreasing trend in losses, both before and after deducting non-recurring gains and losses. It is worth mentioning that on January 17th, Dr. Fang Jianmin, CEO of REMEGEN, delivered a keynote speech at the 43rd J.P. Morgan Healthcare Conference. In 2025, the company will see a series of important developments, including Teysirumab's potential approval for the treatment of myasthenia gravis (MG) in China, Vidisitumab's potential approval for the treatment of HER2-positive liver metastatic breast cancer; while a series of new market applications are expected to be submitted, including Teysirumab for the treatment of IgA nephropathy (IgAN) and primary Sjogren's syndrome (pSS), VEGF/FGF dual-target fusion protein drug RC28 for the treatment of diabetic macular edema (DME), Vidisitumab for first-line treatment of urothelial carcinoma and HER2 low-expression breast cancer indications.